-+ 0.00%
-+ 0.00%
-+ 0.00%

FDA APPROVES KEYTRUDA® (PEMBROLIZUMAB) AND KEYTRUDA QLEX™ (PEMBROLIZUMAB AND BERAHYALURONIDASE ALFA-PMPH), EACH WITH PADCEV® (ENFORTUMAB VEDOTIN-EJFV), AS TREATMENT BEFORE AND AFTER SURGERY FOR ADULTS WITH MUSCLE-INVASIVE BLADDER CANCER (MIBC)

Reuters·07/10/2026 18:10:00

Please log in to view news